ZyVersa Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q2 2022 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
ZyVersa Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q2 2022 to Q2 2024.
  • ZyVersa Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $161K, a 56.1% decline year-over-year.
  • ZyVersa Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $924K, a 23.2% decline year-over-year.
  • ZyVersa Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $1.19M, a 66.2% decline from 2022.
  • ZyVersa Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $3.52M, a 17% decline from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $924K $161K -$205K -56.1% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-09
Q1 2024 $1.13M $224K -$63.9K -22.2% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 $1.19M $297K +$240K +427% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-25
Q3 2023 $953K $243K -$251K -50.8% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-14
Q2 2023 $1.2M $366K -$330K -47.4% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-09
Q1 2023 $1.53M $287K Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 $56.3K Dec 13, 2022 Dec 31, 2022 10-K 2024-03-25
Q3 2022 $494K Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 $696K Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-21
* An asterisk sign (*) next to the value indicates that the value is likely invalid.